The mechanism: why two receptors matters

Semaglutide is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1, a gut hormone that signals fullness, slows gastric emptying, and nudges the pancreas to release insulin when blood sugar is up. It works. The STEP trials showed meaningful weight loss and the diabetes outcomes data is solid. The problem is it’s doing one thing.

Tirzepatide does two things. It’s a dual agonist of GLP-1 and GIP. GIP stands for glucose-dependent insulinotropic polypeptide, and it’s the part most people don’t know about because semaglutide doesn’t touch it. GIP is another gut hormone with its own effects on appetite, fat storage, and energy metabolism. The two receptors aren’t redundant, they’re complementary, and combining them appears to produce effects that go beyond what you’d expect if you just added the two pathways together. The SURMOUNT trial data suggests actual synergy, not just addition, at certain dose ranges.

That’s not a theoretical point. The synergy translates to weight loss numbers that are meaningfully higher than semaglutide achieves at its maximum approved dose. Not slightly better in the noise of measurement error, actually better in direct head-to-head comparison.

Brand names: Mounjaro vs Zepbound

Same drug. Different labels. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. The active ingredient in both is tirzepatide. The dosing schedules are identical. The drug itself is the same molecule coming out of the same Eli Lilly manufacturing process.

Why two brand names? Because FDA approval pathways for diabetes and obesity are separate, the clinical trials that support each indication are different, and the labeling requirements reflect different patient populations. From a practical standpoint the duplication mainly matters for insurance coverage, which I’ll get to, because your plan might cover one label and not the other even though you’re putting the same thing in your body.

If you hear someone say “Mounjaro is better for diabetes and Zepbound is better for weight loss,” that’s not a pharmacological statement. That’s a label statement. The drug is the drug.

What the SURMOUNT trials actually showed

The SURMOUNT program is a series of large randomized controlled trials that tested tirzepatide specifically in people with obesity, with and without diabetes. The headline number from SURMOUNT-1, the flagship obesity trial, is 22.5% average body weight loss at the 15mg dose over 72 weeks. That’s the top-line result and it’s genuinely impressive, but a few things are worth unpacking before you decide what it means for you.

First, 22.5% is the mean at the highest approved dose. The 5mg and 10mg doses showed 15% and 19.5% respectively, so there’s a clear dose response, but not everyone who starts on tirzepatide makes it to 15mg or stays at it comfortably. Second, the trial population had obesity defined as BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition. These aren’t people looking to lose 15 pounds for aesthetics, they’re people with medically meaningful excess weight where the intervention is clearly justified. The biology of who responds best is still being worked out.

Third, and this matters practically: those weight loss numbers are on the drug. The SURMOUNT-4 extension data showed substantial weight regain after discontinuation, consistent with what semaglutide trials showed. This is a long-term medication for people who need long-term intervention, not a reset button you use once.

SURMOUNT-5 was the head-to-head against semaglutide. Tirzepatide produced greater weight loss than semaglutide at comparable doses. The difference wasn’t trivial: roughly 20% versus 14% average weight loss. If the question is just “which drug loses more weight,” the current answer is tirzepatide. That’s not marketing, that’s a randomized trial.

Dosing and the titration schedule

Tirzepatide is a once-weekly subcutaneous injection. You start at 2.5mg and hold there for four weeks before stepping up. The full schedule is six steps: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg, each at four weeks minimum before moving up. In practice that means you’re looking at five to six months before reaching maximum dose, assuming you tolerate each step without needing to slow down.

That’s more steps and more time than semaglutide’s titration, which has four steps (0.25mg, 0.5mg, 1mg, 2.4mg for Wegovy). Some people will find the slower climb more manageable. Others will find it frustrating to wait that long to see full efficacy. Neither reaction is wrong, it’s just the reality of the schedule.

The slow titration exists because the GI side effects, which are real and I’ll get to them, are frontloaded and dose-dependent. Moving up before your gut has adjusted is asking for a bad stretch that could end your trial of the medication entirely. The four-week minimums are clinically motivated, not arbitrary. Plenty of people do need longer at a given dose before they’re comfortable stepping up, and there’s no shame in that.

You don’t have to reach 15mg. The goal is the lowest dose that produces the metabolic effect you’re aiming for with side effects you can live with. Some people respond well at 5mg or 7.5mg and that’s where they stay. Chasing the maximum dose just because the trial data is reported at 15mg isn’t the right framing for an individual prescription.

Side effects: the honest version

The GI side effects of tirzepatide are similar to semaglutide’s: nausea, vomiting, diarrhea, constipation, and bloating, especially during dose increases. They tend to be worst in the first week or two after stepping up and fade somewhat as your body adjusts. For most people they’re manageable and temporary. For some people they’re significant enough to slow down the titration or stop entirely.

There’s some evidence, though it’s not definitive, that tirzepatide’s GI side effects are slightly better tolerated than semaglutide’s at equivalent weight-loss doses. The SURMOUNT-5 head-to-head showed comparable or modestly better tolerability for tirzepatide despite greater efficacy. If you struggled with semaglutide’s nausea, that’s not a guarantee you’ll sail through tirzepatide, but it’s not a reason to assume you won’t either.

The concern that doesn’t get talked about enough is muscle loss. The weight loss from GLP-1 and dual incretin drugs isn’t purely fat. Studies tracking body composition show that a meaningful fraction of the weight lost is lean mass, including muscle. That’s not unique to tirzepatide, it’s a class-wide issue, but it matters because losing muscle has long-term consequences for metabolism, strength, fall risk in older adults, and how your body handles future weight fluctuations. The answer isn’t to refuse the drug. The answer is protein intake at the high end of adequate and progressive resistance training while you’re on it. Both together. Neither one alone does the job. This is the thing most prescribers don’t talk about enough in the initial visit.

Tirzepatide vs semaglutide: the honest comparison

The simple version: tirzepatide produces more weight loss. That’s not a brand preference or a manufacturer claim, it’s what SURMOUNT-5 showed in a randomized head-to-head trial. The mechanism difference, hitting both GIP and GLP-1, produces better outcomes than GLP-1 alone at the doses studied.

The complicated version: semaglutide has a longer track record with more diverse patient populations, a larger volume of real-world data outside trials, and in some formulations better insurance coverage in specific contexts. Ozempic has a decade of post-market safety data behind it in the diabetes indication. Mounjaro and Zepbound are newer and accumulating that record now. If I were putting my own money and body into one of them today, I’d go tirzepatide based on what the trials show. But if someone is already doing well on semaglutide and their coverage is solid, there’s no obvious clinical reason to switch just to switch.

The question that matters is what problem you’re trying to solve. If you’re starting fresh and efficacy is the primary goal and your coverage situation is similar for both, tirzepatide is currently the more effective drug. That might change as more drugs in this class come to market, but that’s where the evidence sits right now.

Compounded tirzepatide

The same compounded market that exists for semaglutide exists for tirzepatide. During FDA shortage periods for branded products, compounding pharmacies can produce tirzepatide-based formulations legally, and the cost advantage is real, often less than a third of the out-of-pocket cost for Mounjaro or Zepbound without insurance coverage.

The caveats are also the same. Compounded medications are not FDA-approved. Quality control is the responsibility of the individual compounding pharmacy, not a centralized regulatory body. Reputable pharmacies with USP 797 compliance and third-party testing exist, but they share a category with operations that are less careful. The base compound, tirzepatide, is the same molecule. What’s variable is purity, concentration accuracy, and sterility assurance. If you go this route, the due diligence step is not optional.

One additional wrinkle with tirzepatide specifically: some compounding pharmacies have used tirzepatide in the form of its salt (tirzepatide base versus specific salt forms) and the FDA flagged concerns about whether these are equivalent. It’s worth asking any compounding pharmacy directly about the specific form they’re using and whether it matches the reference standard for the approved drug. That question alone will tell you something about how seriously they take the details.

Insurance: the part nobody wants to deal with

Coverage for Mounjaro in the diabetes indication is reasonably consistent across major commercial plans when you have a type 2 diabetes diagnosis and an A1c that supports medical necessity. Coverage for Zepbound in the obesity indication is more variable and often requires prior authorization, BMI documentation, evidence of prior weight management attempts, and sometimes comorbid conditions.

The same split exists for semaglutide: Ozempic (diabetes) gets covered more reliably than Wegovy (obesity). The pattern is consistent across GLP-1 and dual incretin drugs. Insurance companies are substantially more comfortable covering these drugs for glycemic control in diabetes than for weight management in obesity, even though the metabolic benefits overlap substantially. The political history of obesity being treated as a lifestyle issue rather than a medical one is baked into the coverage policies.

If you don’t have diabetes and you’re paying out of pocket: Mounjaro and Zepbound without any coverage are expensive, typically in the range of $900-$1,000 per month at retail for the injector pens. Eli Lilly’s savings card can reduce that substantially for eligible patients, but eligibility has income and insurance requirements. Compounded versions exist at much lower cost with the caveats I described above. This is a math problem specific to your situation and worth working through before you start, not after you’ve already been on the drug for three months and get a coverage denial.

The muscle conversation nobody is having at the prescribing visit

I keep coming back to this because I think it’s genuinely underdiscussed in the mainstream conversation about GLP-1 and dual incretin drugs. The trials show substantial weight loss. What they also show, when you look at DEXA scan data and body composition analysis, is that a meaningful fraction of that weight loss is lean mass. In some analyses it’s close to 40% of total weight lost. That’s not a small number.

Muscle loss matters for men specifically. You’re already fighting age-related muscle loss if you’re over 35. Add in an intentional weight loss intervention that accelerates it, and you can come out of a successful course of tirzepatide with a lower scale number but a worse body composition ratio than when you started. Better metabolic health, lighter, but softer and weaker. For most men that’s not actually the full outcome they wanted.

The fix is practical and evidence-supported. Protein intake at 1.2-1.6 grams per kilogram of body weight per day (some research argues higher during active weight loss) combined with progressive resistance training at least three days a week has been shown to substantially preserve lean mass during caloric restriction. The drug creates the caloric deficit. You have to do the work to protect what you’re keeping. That’s not a punishment, it’s just honest physiology.

If your prescribing provider didn’t bring this up, bring it up yourself at the next visit. Ask specifically about body composition tracking, not just weight, and ask about protein targets and exercise prescription. If they can’t engage with that question, that’s information about whether you have the right provider for this.

Mental health and GLP-1 adjacent medications

There’s an emerging and genuinely interesting signal in the research on GLP-1 receptors in the central nervous system. GLP-1 receptors exist in the brain, particularly in areas involved in reward processing, and there’s active investigation of whether GLP-1 and dual incretin drugs have effects beyond metabolic ones, including possible roles in addictive behavior, impulsivity, and mood. Early observational data is intriguing. The mechanism is plausible. The clinical application isn’t established yet.

What’s documented well enough to mention: some people on these medications report significant reductions in food noise, meaning the constant background mental chatter about eating and craving that many people with obesity describe. Some report reductions in alcohol craving and use. Whether that’s a direct pharmacological effect or a downstream consequence of better metabolic regulation is still an open question. It’s worth paying attention to if you’re on tirzepatide and also managing an alcohol use issue or significant compulsive eating patterns, not as a treatment strategy but as a variable to track.

The psychiatric side effect data shows some signal around GI-related mood effects (nausea and fatigue can look a lot like depression symptomatically), and a small number of cases of suicidal ideation have been reported in GLP-1 class post-market surveillance, though causality hasn’t been established and the FDA review of this signal in 2023 concluded the evidence was insufficient to add a warning. Still worth knowing, especially if you have any history of mood disorder.

What this is and what it isn’t

Tirzepatide is a powerful medication with good efficacy data in a specific and medically important application. If your weight is meaningfully affecting your health and you’ve been honest about the lifestyle interventions that are actually sustainable for you and they haven’t been enough, this is a legitimate tool. The trial data is solid. The FDA approved it. The mechanism is understood. These aren’t small things.

It is not a shortcut that lets you skip the other work. It’s not permanent unless you stay on it, and the weight comes back when you stop. It doesn’t protect the muscle you lose unless you put in the effort to protect it. It won’t fix the behavioral and psychological relationships with food that contributed to the problem in the first place, and for some people those are the harder problem anyway. The drug handles one part of a system, and systems require attention to more than one part.

The more useful frame for most men considering it is this: if the biology has been working against you in ways that genuinely aren’t solved by harder trying, this is a pharmacological intervention that can shift the biology enough to make the other work more viable. Lower weight reduces joint pain and sleep apnea and insulin resistance, all of which make exercise easier and more sustainable, which makes maintaining the result more achievable. It’s not a single solution. It can be a lever that changes what the rest of the effort is building toward.